Ginkgo Bioworks Holdings Inc. (DNA) stock soared 5.02% on Wednesday, likely boosted by positive news regarding its partner company Lucid Diagnostics.
Lucid Diagnostics, a commercial-stage cancer prevention medical diagnostics company, announced that its prospective clinical utility study for the EsoGuard® Esophageal DNA Test has been accepted for publication in the peer-reviewed journal Medicina.
The EsoGuard test is designed to detect esophageal precancer and cancer through early detection in at-risk patients. The clinical study demonstrated outstanding clinical utility, including an exceptionally high 85% patient compliance with referral to confirmatory upper endoscopy following EsoGuard testing in a real-world clinical setting.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。